The NLRP3 inflammasome functions as an intracellular sensor of danger. In a first, so-called priming step, pattern-recognition receptors such as Toll-like receptor 4 switch on the transcription factor NF-κB, which ramps up production of inflammasome building blocks, including NLRP3 itself, pro-caspase-1, and the precursor forms of the inflammatory messengers interleukin-1β and interleukin-18. A second, activation step is then triggered by cellular stress signals, prompting the enzyme caspase-1 to slice those precursor cytokines into their mature, secreted forms. In obesity, a steady drip of metabolic damage-associated molecular patterns—free fatty acids, ceramides, uric acid, and reactive oxygen species leaking from stressed mitochondria—keeps both steps running at high throttle. The result is the chronic, low-grade inflammation that underpins insulin resistance, type 2 diabetes, cardiovascular disease, and other obesity-related complications.

To test whether a realistic dietary intervention could quiet this pathway, the Valencia team enrolled 45 adults with obesity, most of them women, with an average body mass index of about 45 kilograms per square meter. The 24-week program began with a six-week very-low-calorie phase in which participants replaced all meals with a liquid formula providing roughly 654 kilocalories per day, followed by an 18-week low-calorie plan modeled on the Mediterranean diet, individually tailored to between 1,200 and 1,800 kilocalories daily. By the end of the intervention, participants had lost an average of nearly 10 percent of their starting body weight, with significant drops in BMI, waist circumference, relative fat mass, and waist-to-height ratio—markers pointing to a genuine reduction in visceral fat, the metabolically troublesome kind most tightly linked to systemic inflammation.

The metabolic dividends were substantial. Blood pressure fell, insulin resistance as measured by the HOMA-IR index improved, fasting insulin and glycated hemoglobin declined, HDL cholesterol rose, and triglycerides dropped. The inflammatory picture improved in parallel: circulating tumor necrosis factor alpha and complement component 3, an emerging marker of metabolic inflammation, both decreased significantly, although interleukin-6 levels remained unchanged. Notably, levels of lipopolysaccharide-binding protein, a surrogate marker for the metabolic endotoxemia thought to leak from a permeable gut in obesity, did not budge—a reminder, the authors caution, that not every inflammatory input responds equally to a six-month diet, and that the smaller sample available for that particular assay warrants careful interpretation.

Where the study broke new ground was in its molecular dissection of the inflammasome itself. Using western blotting on peripheral blood mononuclear cells isolated from participants before and after the intervention, the researchers documented a coordinated shutdown of the priming machinery. Protein levels of NF-κB p65 fell, as did NLRP3, the adaptor protein ASC, and pro-caspase-1. The active p10 fragment of caspase-1 showed a downward trend that narrowly missed statistical significance, hinting that the activation step was also being reined in. Consistent with this, serum concentrations of the inflammasome’s signature cytokines, interleukin-1β and interleukin-18, dropped significantly after the diet. Because these cytokines impair insulin receptor signaling, damage pancreatic beta cells, and promote endothelial dysfunction, their decline suggests a partial breaking of the vicious cycle in which inflammation and metabolic dysfunction feed each other.

The team also traced the upstream triggers that had been fanning the inflammasome’s flames. Nearly half of the participants were hyperuricemic at baseline, and uric acid—a potent danger signal that can prime NLRP3 through Toll-like receptor 4 and activate it by destabilizing lysosomes inside macrophages—fell markedly after weight loss. Oxidative stress, another critical upstream driver, receded on two fronts. Cytosolic superoxide production in the immune cells, visualized with a fluorescent probe under an automated microscopy platform, declined significantly, and plasma levels of 8-hydroxy-2′-deoxyguanosine, a biomarker of oxidative damage to DNA, dropped as well. Since mitochondrial DNA makes up a large share of the cell-free DNA circulating in blood and is especially vulnerable to oxidation, the authors interpret the fall in 8-OHdG as evidence of reduced mitochondrial injury and a diminished supply of oxidized mitochondrial DNA, which can activate NLRP3 by binding directly to its pyrin domain.

Putting the pieces together, the researchers propose that caloric restriction works through a redox-immunometabolic cascade centered on AMP-activated protein kinase, or AMPK, a master nutrient sensor that governs mitochondrial quality control. Previous work by some of the same investigators showed that calorie restriction enhances AMPK signaling, boosts autophagic flux, and remodels mitochondria in immune cells, while impaired autophagy in adipocytes has been linked to NLRP3 activation. In this framework, diet-induced autophagy and mitophagy clear out damaged mitochondria before they can spill reactive oxygen species and oxidized DNA, thereby starving the inflammasome of its activation triggers. The new findings dovetail with animal studies in which genetic deletion or pharmacological blockade of inflammasome components reproduced the metabolic benefits of dietary restriction, and with human trials showing that short-term fasting suppresses NLRP3 in immune cells and that bariatric surgery lowers inflammasome gene expression.

Perhaps the most provocative finding concerns who benefits most. When the team correlated baseline characteristics with the magnitude of change in inflammasome markers, they found that participants who started out with greater central adiposity—higher BMI, larger waist circumference, higher waist-to-height ratio—and with more severe insulin resistance showed smaller reductions in ASC, pro-caspase-1, caspase-1, interleukin-1β, and superoxide. In other words, entrenched metabolic dysfunction appears to blunt the anti-inflammatory payoff of caloric restriction, possibly because a self-sustaining inflammatory-metabolic loop keeps the pathway locked in place. The practical implication is that patients with severe metabolic impairment may need longer interventions, or combined strategies, to unlock the same immunometabolic benefits that a moderate diet delivers to those with a less adverse starting profile.

The authors also flag a potential relevance for women after menopause. Estrogens are known to dampen NLRP3 priming and activation through several mechanisms, and although hormonal status was not recorded in this predominantly female cohort, the team suggests that dietary weight loss may be particularly valuable when estrogen’s natural anti-inflammatory protection wanes—a hypothesis they acknowledge needs dedicated testing. They are careful to note that the six-month timeframe makes it unlikely that hormonal variation, rather than weight loss itself, drove the coordinated improvements they observed.

The study has limits that the authors lay out candidly. It was an observational, single-arm intervention without a randomized control group, so causality cannot be firmly established, and the analysis was confined to circulating mononuclear cells rather than the adipose tissue macrophages that are thought to be a major site of inflammasome activity in obesity. Sample sizes varied across assays because of constraints on biological material, limiting statistical power for some comparisons, and the cohort was not powered to detect sex-specific effects. Still, the integrative design—measuring actual protein expression and downstream cytokine release rather than just messenger RNA, alongside systemic metabolic and oxidative markers—gives the findings unusual mechanistic weight. As the first study to demonstrate that moderate, diet-induced weight loss attenuates the NLRP3 inflammasome in human immune cells while lowering its systemic cytokine output, the work strengthens the case that the oldest weight-loss tool in medicine remains one of the most molecularly sophisticated, and it points toward nutritional or pharmacological strategies that could one day mimic its immunometabolic effects for patients who cannot achieve the weight loss themselves.

Subject of Research: Effects of caloric restriction on NLRP3 inflammasome activation and oxidative stress in leukocytes of patients with obesity

Article Title: Caloric restriction attenuates NLRP3 inflammasome activation and oxidative stress in leukocytes of patients with obesity

Article References: López-Domènech, S., Perea-Galera, L., Pelechá-Salvador, M., Abad-Jiménez, Z., Hermenejildo, J., Fernández-Reyes, M., Luna-Marco, C., Cacace, J., Veses, S., Morillas, C., Víctor, V. M., & Rocha, M. (2026). Caloric restriction attenuates NLRP3 inflammasome activation and oxidative stress in leukocytes of patients with obesity. iScience, 29(11), Article 117743. https://doi.org/10.1016/j.isci.2026.117743

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117743

Keywords: caloric restriction, NLRP3 inflammasome, obesity, inflammation, oxidative stress, PBMCs, interleukin-1beta, insulin resistance, mitochondria, hypocaloric diet, innate immunity, weight loss

The research team, led by Fatemeh Shayesteh and colleagues at Shahrekord University of Medical Sciences in Iran, set out to test whether these two probiotic strains could modulate inflammasome signalling, a pathway increasingly implicated in chronic mucosal inflammation across species. Inflammasomes are cytosolic protein complexes that act as intracellular alarm systems, sensing microbial or endogenous danger signals and activating the enzyme caspase-1. Once activated, caspase-1 cleaves and matures the potent inflammatory cytokines interleukin-1β and interleukin-18, which drive neutrophil recruitment, tissue damage, and the self-perpetuating cycle of inflammation characteristic of colitis. When the NLRP3 inflammasome becomes overactive, as has been documented in both human and veterinary cases of inflammatory bowel disease, the result is persistent mucosal injury and poor healing.

To model the disease, the researchers induced ulcerative colitis in 40 male Wistar rats by administering a single intrarectal dose of 4% acetic acid under anaesthesia, a well-established chemical method that reproduces key histopathological features seen in naturally occurring colitis of dogs, cats, and cattle, including mucosal ulceration, epithelial barrier dysfunction, and infiltration of inflammatory cells. The animals were randomly divided into five groups of eight: a healthy control group receiving saline, an untreated colitis group, a group treated with the standard anti-inflammatory drug mesalazine at 300 mg/kg per day, and two probiotic groups receiving daily oral gavage of either B. coagulans or L. acidophilus at a concentration of 10⁹ colony-forming units per millilitre for seven consecutive days. On day ten, the rats were euthanized and colonic tissues were collected for molecular, biochemical, and histological analysis.

The molecular results were striking. Compared with healthy controls, colitis induction caused dramatic upregulation of inflammasome-related genes in colonic tissue: interleukin-18 expression rose roughly 7.6-fold, NLRP3 about 11-fold, caspase-1 more than 12-fold, and tumour necrosis factor-alpha more than 6-fold. Treatment with either probiotic strain significantly reversed these changes. In the L. acidophilus group, expression of all four genes fell substantially relative to untreated colitis animals, and B. coagulans produced reductions of similar magnitude. Notably, the probiotic effects were comparable to those achieved with mesalazine, the benchmark therapy, which itself suppressed the same gene set. The convergence of probiotic and pharmacological outcomes at the transcript level suggests that these bacteria engage the same inflammatory circuitry that conventional drugs target, but through biological mechanisms rather than chemical inhibition.

Protein-level measurements reinforced the gene expression data. Using enzyme-linked immunosorbent assays on colonic tissue homogenates, the team found that colitis induction caused enormous increases in interleukin-1β and interleukin-17 protein concentrations. Both probiotics significantly lowered these cytokines, again paralleling the effect of mesalazine. Interleukin-1β is the direct downstream product of caspase-1 activation within the inflammasome, so its reduction provides functional confirmation that probiotic treatment genuinely dampens inflammasome output rather than merely altering gene transcription. Interleukin-17, meanwhile, is a signature cytokine of the Th17 immune axis that drives neutrophil recruitment and barrier disruption, meaning the probiotics appeared to suppress inflammation at multiple points along the pathological cascade.

The structural evidence was equally persuasive. Macroscopic examination of the colons, scored independently by two blinded observers using the Wallace and Keenan system, revealed severe ulceration, hyperaemia, inflammation, and oedema in untreated colitis animals, with a mean wound score of 3.25. Both probiotic groups showed marked improvement, with L. acidophilus achieving a mean score of 1.50, identical to the mesalazine group, and B. coagulans scoring 1.83. Colon length and weight, which serve as indirect measures of tissue oedema and shortening, were significantly restored in both probiotic groups compared with the untreated colitis group, indicating that the bacteria helped preserve gross tissue morphology.

Under the microscope, the differences were just as clear. Haematoxylin and eosin stained sections from untreated colitis rats displayed pronounced thickening of the mucosal, submucosal, and muscularis layers, extensive epithelial cell loss, a marked reduction in goblet cells, severe leukocyte infiltration, and lymphoid hyperplasia across all tissue layers. In contrast, sections from probiotic-treated animals showed reduced layer thickness, fewer inflammatory cells, milder crypt damage, and tissue involvement confined to the 1 to 25% range, compared with 51 to 75% in the colitis group. Histopathological scores fell from 4 in the colitis group to 2 in both probiotic groups, matching the mesalazine-treated animals. The restoration of goblet cells, which produce the protective mucus layer lining the gut, points to genuine epithelial repair rather than simple suppression of visible inflammation.

The mechanistic story behind these findings is likely multifaceted. Probiotics are known to reinforce epithelial integrity, compete with pathogenic bacteria for adhesion sites and nutrients, produce antimicrobial compounds, and regulate immune cell activity through Toll-like receptor pathways and the production of short-chain fatty acids. The authors suggest that suppression of inflammasome signalling may occur indirectly through these routes: by modulating Toll-like receptor activation, probiotics can shift the danger-sensing environment of the gut mucosa away from the chronic alarm state that keeps NLRP3 primed. Each strain also brings distinct practical advantages. B. coagulans is a spore-forming lactic acid bacterium whose resilient spores survive harsh storage conditions and the acidic gauntlet of the gastrointestinal tract, a trait particularly valuable in farm settings. L. acidophilus, by contrast, is a strong colonizer of the intestinal tract with well-documented immunomodulatory properties, making it well suited to companion animals with chronic enteropathies.

The veterinary implications extend well beyond the laboratory. Chronic inflammatory gut diseases reduce productivity in livestock, impair growth in young animals, and increase morbidity in pets, while long-term drug therapy raises concerns about cost, side effects, and, in food animals, drug residues in the food supply. Probiotics that measurably reduce inflammasome activation and pro-inflammatory cytokines could serve as adjuncts that allow lower doses of conventional drugs, or as standalone interventions in milder cases. The study also fits into a broader trend in veterinary microbiology toward multi-strain formulations, since combinations of Bacillus and Lactobacillus species are thought to target different aspects of gut ecology and immune regulation simultaneously, potentially offering synergistic benefits over single-strain products.

Important caveats remain. Some inflammation and leukocyte infiltration persisted even in probiotic-treated animals, indicating that these bacteria alleviate disease severity but may not fully replace pharmacological therapy in severe cases. Moreover, the murine model, while translational, differs from dogs, cats, and livestock in microbiota composition and immune function, so clinical trials in target veterinary species are the necessary next step, along with optimization of dosing regimens and formulation of multi-strain products tailored to different animal populations. Still, by connecting a practical, shelf-stable probiotic pair to a specific molecular pathway central to colitis pathology, the study provides a mechanistic bridge between the empirical use of probiotics in animal health and the modern immunology of inflammatory disease, and it does so with the kind of rigorous, multi-level evidence, from gene expression to protein to tissue architecture, that could finally move veterinary probiotics from folklore to pharmacology.

Subject of Research: Probiotic modulation of NLRP3 inflammasome signalling in experimental ulcerative colitis

Article Title: Probiotic Intervention With Bacillus coagulans and Lactobacillus acidophilus in Small Animals Experimental Ulcerative Colitis: Insights From a Small Animal Model

Article References: Shayesteh, F., Shahini Shams Abadi, M., Rouhi, L., Doosti, A., & Bagheri, N. (2026). Probiotic Intervention With Bacillus coagulans and Lactobacillus acidophilus in Small Animals Experimental Ulcerative Colitis: Insights From a Small Animal Model. Veterinary Medicine and Science, 12(6), Article e70883. https://doi.org/10.1002/vms3.70883

Image Credits: AI Generated

DOI: 10.1002/vms3.70883

Keywords: probiotics, Bacillus coagulans, Lactobacillus acidophilus, ulcerative colitis, NLRP3 inflammasome, veterinary medicine, inflammatory bowel disease, interleukin-1beta, mesalazine, rat model, gut microbiota, cytokines